Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10
This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors.
Original patent title: “Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby”
This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors. Granted to University of Pennsylvania in 2022 with 20 claims, and it is expected to expire in 2041.
Coverage
What does this patent actually cover?
The patent claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → a "cultured host cell" that has been genetically modified. This cell contains a "recombinant nucleic acid molecule" (an engineered piece of DNA) that carries instructions for two main things: first, making specific parts of the AAVrh.10 virus, such as its "vp1 capsid protein" (amino acids 1 to 738 of SEQ ID NO: 81), or vp2, or vp3, or specific nucleotide sequences (like 845 to 3058 of SEQ ID NO: 59); and second, a "heterologous non-AAV sequence." This "heterologous" part is the therapeutic genetic material that a gene therapy aims to deliver. For example, a cell could be engineered to produce the outer shell of the AAVrh.10 virus, while also carrying the gene for a missing protein in a patient. Some claims also specify the presence of a "functional rep gene" (which helps the virus replicate) and that the recombinant molecule can be a "plasmid" (a common way to introduce DNA into cells).
The gap
What does this patent NOT cover?
- Does not cover AAVrh.10 sequences or proteins existing outside of a cultured host cell.
- Does not cover host cells containing AAVrh.10 components without an additional "heterologous non-AAV sequence."
- Does not cover other types of adeno-associated viruses (AAVs) beyond the specific AAVrh.10 variant described.
- Does not cover gene therapy vectors that use entirely different viral or non-viral delivery systems.
- Does not cover cells containing only the AAV 'rep gene' without the specified capsid protein or nucleotide sequences.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The noveltynoveltyThe requirement that an invention be different from anything publicly known before its priority date.Read more → lies in precisely defining and claiming the use of specific AAVrh.10 capsid protein sequences (like VP1, VP2, VP3 from SEQ ID NO: 81) or specific nucleic acid sequences (from SEQ ID NO: 59) within a cultured host cell, specifically combined with a "heterologous non-AAV sequence" for gene delivery applications. This focuses on a particular, potentially advantageous, AAV serotype for vector production.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Manufacturing of gene therapy vectors in bioreactors
Research into new gene therapies for genetic disorders
Production of AAV-based vaccines in laboratory settings
Why it matters
The bigger picture
Adeno-associated viruses (AAVs) are widely used in gene therapy because they can deliver genetic material into cells safely and efficiently. The University of Pennsylvania, particularly through Dr. James Wilson's lab, has been a pioneer in identifying and developing different AAV serotypes, like AAVrh.10, which can have unique properties for targeting specific tissues or evading immune responses. This patent protects the specific engineering of cells to produce gene therapy vectors using this particular AAVrh.10 variant, which is crucial for developing new treatments for genetic diseases.
Filed
October 12, 2021
Granted
November 15, 2022
Market context
Who's building on this
Companies in this space
The University of Pennsylvania, through its gene therapy program, continues to be a leader in AAV research and development. Companies like Sarepta Therapeutics, Novartis, and Pfizer are actively developing AAV-based gene therapies, often licensing or building upon foundational AAV technologies developed by academic institutions. Many biotechnology startups also focus on optimizing AAV vectors for various therapeutic applications.
Market impact
The development and patenting of specific AAV serotypes, like AAVrh.10, have significantly expanded the toolkit available for gene therapy. This has enabled the creation of new gene therapy candidates with potentially improved tissue targeting, reduced immunogenicity, or better manufacturing properties. Such patents contribute to the intellectual property landscape that underpins the multi-billion dollar gene therapy market, influencing licensing agreements and competitive strategies among pharmaceutical and biotech companies.
Claim 1 — Plain English
What this patent covers
The patent claims a "cultured host cell" that has been genetically modified. This cell contains a "recombinant nucleic acid molecule" (an engineered piece of DNA) that carries instructions for two main things: first, making specific parts of the AAVrh.10 virus, such as its "vp1 capsid protein" (amino acids 1 to 738 of SEQ ID NO: 81), or vp2, or vp3, or specific nucleotide sequences (like 845 to 3058 of SEQ ID NO: 59); and second, a "heterologous non-AAV sequence." This "heterologous" part is the therapeutic genetic material that a gene therapy aims to deliver. For example, a cell could be engineered to produce the outer shell of the AAVrh.10 virus, while also carrying the gene for a missing protein in a patient. Some claims also specify the presence of a "functional rep gene" (which helps the virus replicate) and that the recombinant molecule can be a "plasmid" (a common way to introduce DNA into cells).
The clever bit
The novelty lies in precisely defining and claiming the use of specific AAVrh.10 capsid protein sequences (like VP1, VP2, VP3 from SEQ ID NO: 81) or specific nucleic acid sequences (from SEQ ID NO: 59) within a cultured host cell, specifically combined with a "heterologous non-AAV sequence" for gene delivery applications. This focuses on a particular, potentially advantageous, AAV serotype for vector production.
What it does not cover
- Does not cover AAVrh.10 sequences or proteins existing outside of a cultured host cell.
- Does not cover host cells containing AAVrh.10 components without an additional "heterologous non-AAV sequence."
- Does not cover other types of adeno-associated viruses (AAVs) beyond the specific AAVrh.10 variant described.
- Does not cover gene therapy vectors that use entirely different viral or non-viral delivery systems.
- Does not cover cells containing only the AAV 'rep gene' without the specified capsid protein or nucleotide sequences.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
Patent enters public domain
PatentBrief Score
Impact Score
Moderate
Citation count
0/40
No citations yet
Claim breadth
13/20
Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
20/20
Major company or institution
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$88K – $281K
Midpoint $176K · 14.9 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
20 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Wilson, J. M., Alvira, M. R., & Gao, G. (2022). Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10 (U.S. Patent No. 11,499,167). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/11499167/method-of-detecting-andor-identifying-adeno-associated-virus-aav-sequences-and-i
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US11499167"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 11357868 · 2022 · University of Pennsylvania
New Adeno-Associated Virus Capsids for Gene Therapy
US 12735721 · 2026
Engineered AAV Vectors for Targeted Gene Delivery to Specific Body Parts
US 12735723 · 2026
Treating Muscular Dystrophy with a Self-Complementary AAV Gene Therapy
US 4703008 · 1987 · Kirin Amgen Inc
How to Make Human Erythropoietin (EPO) Using Engineered DNA
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10 cover?
This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors.
Who owns patent US 11499167?
University of Pennsylvania owns this patent, granted in 2022.
When does this patent expire?
This patent is expected to expire on October 12, 2041, when the invention enters the public domain.
What problem does this patent solve?
Adeno-associated viruses (AAVs) are widely used in gene therapy because they can deliver genetic material into cells safely and efficiently. The University of Pennsylvania, particularly through Dr. James Wilson's lab, has been a pioneer in identifying and developing different AAV serotypes, like AAVrh.10, which can have unique properties for targeting specific tissues or evading immune responses. This patent protects the specific engineering of cells to produce gene therapy vectors using this particular AAVrh.10 variant, which is crucial for developing new treatments for genetic diseases.
What does this patent NOT cover?
Does not cover AAVrh.10 sequences or proteins existing outside of a cultured host cell.
Same assignee
More from University of Pennsylvania
Patent monitoring



